A novel drug gets Breakthrough Designation in combination with Opdivo® in Melanoma
Background Bempegaldesleukin, NKTR-214, and nivolumab, Opdivo, was granted breakthrough deisgnation by the FDA for the first line treatment of patients with previously untreated unresectable or metastatic melanoma. Bempegaldesleukin, NKTR-214, is…
